Lipid lowering drugs, inflammation and cardiovascular disease

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 3, 2003, Pages 178-182

  Schachter, Michael ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Atherosclerosis; C reactive; Cardiovascular disease; Inflammation; Protein; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CIPROFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; PRAVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE MARKER; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; REVIEW;

EID: 0037560474     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030030401     Document Type: Review

References (44)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-26.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
3. Blake GJ, Ridker PM. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J 2001;2:796-800.
4. Ludewig B, Zinkernagel RM, Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc Med 2002;12:154-9.
5. Marathe GK, Prescott SM. Zimmerman GA, McIntyre TM. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med 2001;11:139-42.
6. Yla-Herttuala S. Oxidized LDL and atherogenesis. Ann NY Acad Sci 1999;874:134-7.
7. Zebrack JS, Anderson JL. The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease. Curr Cardiol Rep 2002;4:278-88.
8. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emergic risk factor in cardiovascular disease. JAMA 2002;288:2724-31.
9. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403.
10. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 2002;23:831-4.
11. Bell DS. Inflammation, insulin resistance, infection, diabetes, and atherosclerosis. Endocr Pract 2000;6:272-6.
12. Cahn JC, Cheung JC, Stehouwer CD et al. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome - an analysis by structural equation modelling. Int J Obes Relat Metab Disord 2002;26:994-1008.
13. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71.
14. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001;88(suppl):10K-15K.
15. Pepys MB, Hirschfield GM. C-reactive protein and its role in the pathogenesis of myocardial infarction. Ital Heart J 2001;2:804-06.
16. Ridker PM, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
17. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
18. Bickel C, Rupprecht HJ, Blankenberg S et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:901-08.
19. Bermudez EA, Ridker PM. C-reactive protein (CRP), statins, and the primary prevention of atherosclerotic cardiovascular disease. Prev Cardiol 2002;5:42-6.
20. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-18.
21. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2002;144:233-8.
22. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87: 1451-8.
23. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002;97:105-16.
24. Veillard NR, Mach F. Stains: the new aspirin? Cell Mol Life Sci 2002;59: 1771-86.
25. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21:1712-19.
26. Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002;13: 1673-81.
27. Mach F. Immunosuppressive effects of statins. Atheroscler Suppl 2002; 3(1):17-20.
28. Waters DD. Early pharmacologic intervention and plaque stability in acute coronary syndromes. Am J Cardiol 2001;88(suppl):30K-36K.
29. Newby LK, Kristinsson A, Bhakpar MV et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287: 3087-95.
30. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
31. Bickel C, Rupprecht HJ, Blankenberg S et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol 2002;82:25-31.
32. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels. Circulation 2001;103:1933-5.
33. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolaemia. Int J Cardiol 2001;77:247-53.
34. Wiklund O, Mattson-Hultén L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002;251:338-47.
35. Rezaie-Majd A, Maca T, Bucek RA et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194-9.
36. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-52.
37. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002;40:49-55.
38. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001;169:453-9.
39. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effects of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002;53:273-7.
40. Cyrus T, Sung S, Zhao L, Funk C, Tang S, Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor deficient mice. Circulation 2002;106: 1282-7.
41. Park Y-B, Choi HK, Kim M-Y et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002;113:188-93.
42. Cascieri MA. The potential for novel anti-inflammatory therapies for coronary artery disease. Nat Rev Drug Discov 2002;1:122-30.
43. Aikawa M, Sugiyama S, Hill CC et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002;106:1390-6.
44. Buemi M, Senatore M, Corica F et al. Are there potential non-lipid-lowering uses of statins in the kidney? Nephron 2001;89:363-8.